G. Brown

发表

Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra®, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome

R. Larson, Z. Estrov, J. Keck, 2009, Journal of hematology & oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Phase I Study of TLK 286 ( Glutathione S-Transferase P 1-1 Activated Glutathione Analogue ) in Advanced Refractory Solid Malignancies 1

J. Keck, R. Lum, S. Schow, 2003 .

Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignancies.

J. Keck, R. Lum, S. Schow, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase 1 Study of TLK286 (Telcyta) Administered Weekly in Advanced Malignancies

J. Keck, K. Patel, L. Rosen, 2004, Clinical Cancer Research.

TLK286, a novel glutathione analog prodrug, induces resensitization to carboplatin in human ovarian cancer, OVCAR3, platinum resistant cells

J. Keck, Hua Xu, G. Brown, 2005 .

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)

Scott E. Smith, G. Garcia-Manero, D. Steensma, 2012, Journal of Hematology & Oncology.

A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate‐1 risk myelodysplastic syndrome

Scott E. Smith, S. Faderl, D. Mahadevan, 2012, Cancer.

Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra®, TLK199) in Combination with Lenalidomide (Revlimid®) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Scott E. Smith, G. Garcia-Manero, D. Steensma, 2011 .

Gene Expression Studies May Identify Lower Risk Myelodysplastic Syndrome Patients Likely to Respond to Therapy with Ezatiostat Hydrochloride (TLK199)

J. Mesirov, P. Tamayo, O. Botvinnik, 2011 .

Induction of apoptosis by TLK199 in human leukemia cells

J. Keck, A. Raza, G. Brown, 2008 .

Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Scott E. Smith, D. Mahadevan, A. Raza, 2010 .

Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer

I. Vergote, J. Keck, C. Runowicz, 2010, International Journal of Gynecologic Cancer.

Oral ezatiostat HCl (Telintra®, TLK199) and Idiopathic Chronic Neutropenia (ICN): a case report of complete response of a patient with G-CSF resistant ICN following treatment with ezatiostat, a glutathione S-transferase P1-1 (GSTP1-1) inhibitor

G. Brown, R. Lyons, S. Wilks, 2011, Journal of hematology & oncology.

Phase 3 Study: Canfosfamide (C, TLK286) plus carboplatin (P) vs liposomal doxorubicin (D) as 2nd line therapy of platinum (P) resistant ovarian cancer (OC)

T. Kolevska, C. Runowicz, G. Brown, 2007 .

Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome.

Scott E. Smith, J. Keck, J. Lancet, 2009, Blood.

Hematologic Improvement Following Treatment with TLK199 (Telintra™), a Novel Glutathione Analog Inhibitor of GST P1-1, in Myelodysplastic Syndrome (MDS): Interim Results of a Dose-Ranging Phase 2a Study.

Z. Estrov, H. Burris, K. Patel, 2004 .

Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer

R. Bast, P. Ramirez, Marsha Jones, 2010, Journal of hematology & oncology.

PEGylated human IL-10 (AM0010) in combination with pembrolizumab in anti-PD1 and CTLA-4 refractory melanoma.

F. Janku, J. Infante, A. Naing, 2017 .

Phase 1-2a Multicenter Dose-Ranging Study of Canfosfamide in Combination with Carboplatin and Paclitaxel as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer

T. Kolevska, L. Sequist, P. Fidias, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Single agent, canfosfamide (C, TLK286) vs pegylated liposomal doxorubicin (D) or topotecan (T) in 3rd-line treatment of platinum (P) refractory or resistant ovarian cancer (OC): Phase 3 study results

D. Matei, S. Kaye, D. Spriggs, 2007 .

Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome

J. Mesirov, P. Tamayo, O. Botvinnik, 2012, Journal of Hematology & Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome.

Scott E. Smith, J. Keck, J. Lancet, 2009, Blood.